Becton Dickinson and Co (BDX) Shares Sold by Union Bankshares Corp

Union Bankshares Corp decreased its stake in Becton Dickinson and Co (NYSE:BDX) by 7.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,445 shares of the medical instruments supplier’s stock after selling 1,528 shares during the quarter. Union Bankshares Corp’s holdings in Becton Dickinson and were worth $4,607,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. IMS Capital Management purchased a new position in shares of Becton Dickinson and during the 3rd quarter worth about $29,000. Nalls Sherbakoff Group LLC bought a new position in Becton Dickinson and during the 4th quarter worth $34,000. Aspire Private Capital LLC bought a new position in Becton Dickinson and during the 4th quarter worth $39,000. Sontag Advisory LLC bought a new position in Becton Dickinson and during the 4th quarter worth $43,000. Finally, JCIC Asset Management Inc. bought a new position in Becton Dickinson and during the 4th quarter worth $54,000. Institutional investors and hedge funds own 84.82% of the company’s stock.

BDX has been the topic of several recent analyst reports. Morgan Stanley decreased their price target on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Raymond James decreased their price target on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, March 19th. Citigroup decreased their price target on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating on the stock in a research note on Wednesday, January 2nd. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Finally, Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 price target on the stock in a research note on Tuesday, January 8th. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $255.75.

Shares of BDX opened at $252.23 on Thursday. The firm has a market capitalization of $67.87 billion, a PE ratio of 22.91, a price-to-earnings-growth ratio of 1.76 and a beta of 1.21. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $265.87. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.58 by $0.12. The business had revenue of $4.16 billion for the quarter, compared to analyst estimates of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. Becton Dickinson and’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS. Equities research analysts expect that Becton Dickinson and Co will post 12.09 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were given a dividend of $0.77 per share. The ex-dividend date was Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a yield of 1.22%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

In other Becton Dickinson and news, EVP Ribo Alberto Mas sold 2,104 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $255.00, for a total transaction of $536,520.00. Following the completion of the sale, the executive vice president now directly owns 19,074 shares of the company’s stock, valued at approximately $4,863,870. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 3,123 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $796,458.69. Following the sale, the chief executive officer now directly owns 215,372 shares of the company’s stock, valued at $54,926,321.16. The disclosure for this sale can be found here. Insiders have sold a total of 29,684 shares of company stock worth $7,518,574 in the last 90 days. 0.12% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This article was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.wkrb13.com/2019/04/11/becton-dickinson-and-co-bdx-shares-sold-by-union-bankshares-corp.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Limitations of the P/E Growth ratio

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.